Resmetirom

Introduction Overview

Generic Name

resmetirom

Brand Name

Rezdiffra

Dosage Form

oral tablets (60 mg, 80 mg, 100 mg)

Drug Class

Miscellaneous metabolic agents

Pharmacokinetics

Absorption:
Resmetirom is administered orally and exhibits good bioavailability, allowing for effective systemic exposure when taken by mouth. Its absorption kinetics enable once-daily dosing, facilitating patient adherence. The drug’s pharmacokinetic profile is characterized by consistent plasma concentration levels, with peak plasma concentrations typically achieved within a few hours of dosing. Food intake does not significantly affect the absorption of Rezdiffra, making it convenient for administration with or without meals. Clinical pharmacology studies have demonstrated dose-proportional pharmacokinetics across the 60 mg to 100 mg dosing range, supporting flexible dosing tailored to patient body weight.

Distribution:
After absorption, resmetirom binds preferentially to thyroid hormone receptor-beta isoforms predominantly present in hepatic tissue, which facilitates its targeted pharmacodynamic effects. The drug exhibits a moderate volume of distribution, indicating dissemination into tissues beyond plasma. Plasma protein binding is reasonable, limiting extensive free drug circulation but allowing sufficient hepatic exposure. Distribution studies suggest limited penetration across the blood-brain barrier, reducing potential central nervous system side effects. Tissue distribution favors liver uptake, consistent with its mechanism to reduce hepatic fat content.

Metabolism:
Resmetirom is extensively metabolized primarily via hepatic cytochrome P450 enzyme activity, chiefly by CYP2C8, with minor contributions from other isoenzymes. The metabolism results in the formation of several inactive metabolites that are primarily excreted renally and hepatically. The involvement of CYP2C8 has clinical implications, as concomitant use with CYP2C8 inhibitors or inducers can alter resmetirom plasma levels, necessitating dose adjustments or avoidance. The drug’s metabolism is subject to some interpatient variability, but these effects are generally predictable and manageable within clinical dosing protocols.

Elimination:
Elimination of resmetirom and its metabolites occurs via combined renal and biliary excretion. Approximately equal proportions are eliminated through urine and feces, reflecting metabolism and biliary excretion pathways. The elimination half-life supports once-daily administration, with steady-state concentrations reached after consistent dosing over several days. The drug’s clearance parameters remain stable in patients with mild hepatic impairment but are contraindicated in moderate to severe liver disease due to risk of accumulation and toxicity. Renal function appears to have minimal impact on elimination, but monitoring is advised in severe renal impairment due to limited clinical data.

Dosage Forms

Available Dosage Forms:
Rezdiffra is available exclusively as oral tablets formulated in strengths of 60 mg, 80 mg, and 100 mg. The tablet is film-coated for ease of swallowing and to ensure stability and bioavailability.

Dosages for Adults and Adolescents:
The recommended dosing regimen is based primarily on body weight. Adults with body weight less than 100 kg are typically prescribed 80 mg once daily, while those weighing 100 kg or more receive 100 mg once daily. The tablets are administered by mouth once per day, with the ability to be taken with or without food.

Specific Patient Populations:
Dosing adjustments must be carefully considered in patients with hepatic impairment. Rezdiffra is contraindicated in patients with moderate to severe liver disease (Child-Pugh Class B or C) due to risks of hepatotoxicity and altered metabolism. There are no established dosing guidelines for pediatric populations, and its safety and efficacy in patients under 18 years old have not been established. Liver enzyme monitoring is advised throughout therapy to mitigate the risk of liver injury.
Additional dosing considerations include potential interactions with certain medications, necessitating dose modifications or avoidance in the presence of strong CYP2C8 inhibitors or OATP1B1/1B3 inhibitors.

Mechanism Of Action

Resmetirom is a potent, selective agonist of the thyroid hormone receptor-beta (THR-beta), a nuclear receptor predominantly expressed in the liver. Binding of resmetirom to THR-beta initiates transcriptional changes in target genes involved in lipid metabolism. These genomic effects lead to enhanced fatty acid oxidation, decreased lipogenesis, and improved cholesterol metabolism within hepatocytes. By activating these receptors selectively, resmetirom spares thyroid receptor-alpha present in cardiac and skeletal muscle tissues, thereby minimizing cardiovascular side effects associated with nonspecific thyroid hormone therapies.

At the molecular level, resmetirom promotes upregulation of genes responsible for mitochondrial biogenesis and beta-oxidation enzymes, facilitating clearance of triglycerides accumulated in the liver. This biochemical modulation reduces hepatic steatosis, the primary pathological hallmark of nonalcoholic steatohepatitis (NASH). The activation of THR-beta encourages reverse cholesterol transport and decreases plasma low-density lipoprotein (LDL) cholesterol concentrations, providing favorable effects on lipid profiles.

Clinical studies indicate that resmetirom’s selective targeting of THR-beta results in diminished hepatic inflammation and fibrosis progression by mitigating lipid-induced hepatocellular injury. Unlike traditional systemic thyroid hormones, resmetirom's hepatic specificity reduces off-target effects on cardiac and bone systems. Comparative studies have shown that resmetirom's mechanism offers a novel therapeutic approach differing fundamentally from existing agents such as peroxisome proliferator-activated receptor (PPAR) agonists or farnesoid X receptor (FXR) modulators used in NASH.

Ongoing research and phase 3 clinical trials corroborate the clinical benefits of THR-beta agonism, with evidence of histologic improvement in liver fibrosis, attenuation of liver enzymes, and lipid lowering. These findings support resmetirom as a disease-modifying agent that acts at the receptor level to reverse or stall progression of NASH-linked hepatic pathology.

Pharmacological Actions

Selective agonist activity at thyroid hormone receptor-beta isoforms.
Enhancement of hepatic fatty acid oxidation leading to reduced liver fat accumulation.
Modulation of cholesterol metabolism resulting in decreased LDL cholesterol levels.
Reduction of hepatic inflammation and prevention of fibrosis progression.
Improvement of liver histology markers in nonalcoholic steatohepatitis (NASH).
Minimal activity at thyroid hormone receptor-alpha, limiting cardiac side effects.
Hepatic-specific metabolic regulation with limited systemic thyroid hormone effects.
Activation of mitochondrial biogenesis pathways in hepatocytes.
Downregulation of lipogenic gene expression in liver tissue.
Facilitation of reverse cholesterol transport mechanisms.
Dose-dependent pharmacodynamic effect correlating with receptor activation.
Demonstrated anti-fibrotic and anti-steatotic effects in clinical trials.
Potential reduction of triglycerides in plasma and hepatic tissue.
Improvement in lipid and liver enzyme biomarkers in treated patients.
Unique mechanism differing from other NASH therapies focused on metabolic modulation.

Therapeutic Or Clinical Uses

Treatment of nonalcoholic steatohepatitis (NASH) in adult patients with moderate to advanced liver fibrosis.
Adjunctive therapy alongside diet and exercise to reduce hepatic fat content.
Reduction of liver fibrosis progression in chronic metabolic liver disease.
Improvement of liver histology and inflammation markers in NASH.
Lowering of elevated LDL cholesterol in patients with fatty liver disease.
Management of metabolic dysfunction-associated steatohepatitis (MASH).
Potential use under accelerated FDA approval as a disease-modifying agent in advanced liver disease.
Therapy to improve liver enzyme levels indicative of hepatocellular injury.
Non-generic treatment option for patients with no alternative FDA-approved therapies for NASH fibrosis.
Clinical use in patients without decompensated liver cirrhosis.
Monotherapy option for NASH patients contraindicated or intolerant to other agents.
Treatment aimed at reducing triglyceride accumulation in hepatocytes.
Use in patients with stable liver status as a preventive measure against progression to cirrhosis.
Therapeutic option characterized by once-daily oral tablet administration.
Potential to improve patient quality of life by reducing liver disease-related complications.

Side Or Adverse Effects

Liver injury including hepatotoxicity manifesting as elevated liver enzymes and jaundice.
Gallbladder-related adverse events such as cholelithiasis (gallstones).
Cholecystitis, or inflammation of the gallbladder.
Pancreatitis associated with gallstones secondary to treatment.
Gastrointestinal disturbances including diarrhea and constipation.
Nausea and vomiting potentially impacting nutritional intake.
Pruritus (itching) occurring in treated patients.
Abdominal pain, typically in upper right quadrant.
Dizziness reported as a common neurological side effect.
Fever and rash possibly indicative of hypersensitivity or liver inflammation.
Potential transient fatigue during initial treatment phase.
Risk of liver enzyme elevations requiring close monitoring.
Possible dyspepsia and other gastrointestinal discomforts.
Side effects necessitating drug discontinuation in severe cases.
Reports of allergic-type reactions, although rare.

Precautions

Use with caution in patients with any liver disorders other than NASH.
Monitor liver enzyme levels regularly to detect hepatotoxicity early.
Assess and monitor gallbladder function before and during therapy.
Avoid use in patients with known moderate to severe hepatic impairment (Child-Pugh B or C).
Evaluate potential drug interactions especially with CYP2C8 and OATP1B inhibitors.
Adjust dosage or avoid concomitant use with strong CYP2C8 inhibitors such as gemfibrozil.
Limit statin doses when used concurrently due to increased risk of side effects.
Counsel patients on signs and symptoms of liver injury and gallbladder complications.
Pregnancy status should be assessed; the safety profile in pregnant women is unknown.
Breastfeeding mothers should discuss risks and benefits with healthcare providers.
Not recommended for pediatric use due to lack of safety and efficacy data.
Advise patients to report any abdominal pain, jaundice, or unusual fatigue promptly.
Consider potential interactions with immunosuppressants such as cyclosporine.
Regular clinical and laboratory assessments to ensure therapy safety and efficacy.
Educate patients on adherence and proper administration schedules.

Warnings

Risk of liver toxicity requiring frequent monitoring of liver function tests.
Contraindicated in moderate to severe liver disease due to increased risk of adverse effects.
Potential for serious gallbladder-related adverse reactions including cholelithiasis and cholecystitis.
Not established as safe or effective in pediatric populations under 18 years old.
May cause symptoms indicative of liver injury such as jaundice, abdominal pain, fever, and fatigue.
Patients should discontinue treatment and seek immediate medical attention if symptoms of liver injury occur.
Use with caution in patients taking concomitant medications metabolized by CYP2C8 enzyme.
Possible drug interactions leading to increased toxicity or decreased effectiveness.
Monitoring is essential to detect progression towards decompensated liver disease.
Pregnancy risk cannot be ruled out; consultation with healthcare providers is mandatory.
Liver enzyme elevations may require dose adjustments or treatment discontinuation.
Beware of gallstone-induced pancreatitis as a potential severe adverse effect.
Careful assessment is necessary before initiation in patients with preexisting gallbladder disease.
Long-term safety profile is still being established under accelerated approval status.
Withdrawal symptoms or rebound effects on hepatic metabolism have not been established.

Contraindication

Known hypersensitivity or allergy to resmetirom or any excipients in Rezdiffra tablets.
Patients with moderate to severe liver impairment classified as Child-Pugh Class B or C.
Decompensated liver cirrhosis or hepatic failure.
Use with strong CYP2C8 inhibitors such as gemfibrozil (concomitant use not recommended).
Concomitant use with OATP1B1 and OATP1B3 inhibitors like cyclosporine (concomitant use not recommended).
Patients with active gallbladder disease not stabilized prior to treatment.
Pediatric patients under 18 years of age due to safety concerns and lack of data.
Pregnant women unless potential benefits outweigh unknown risks after consultation.
Patients with severe hypersensitivity reactions to other thyroid hormone analogs may be at increased risk.
Concomitant use with medications highly dependent on CYP2C8 metabolism without dose adjustment.
Patients with unstable or rapidly progressing hepatic disease conditions.
Any situation where liver function tests are significantly abnormal prior to therapy initiation.
Individuals with documented intolerance or previous adverse reactions to resmetirom.
Known severe gastrointestinal disorders which may impair absorption and drug efficacy.
Patients unable to comply with liver function monitoring protocols.

Drug Interactions

Strong CYP2C8 inhibitors such as gemfibrozil significantly increase resmetirom plasma levels and are contraindicated with Rezdiffra.
Moderate CYP2C8 inhibitors like clopidogrel require dosage reduction of Rezdiffra to minimize toxicity.
OATP1B1 and OATP1B3 inhibitors, including cyclosporine, can increase resmetirom exposure; concomitant use is not recommended.
Statins such as atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin require dose limitation when used with Rezdiffra due to additive risk of side effects.
CYP2C8 substrates like loperamide, montelukast, and paclitaxel may have increased toxicity risk when administered concomitantly.
Potential pharmacokinetic interactions with immunosuppressants necessitate monitoring and possible dose adjustments.
No significant interaction with food; can be administered without regard to meals.
Drugs that alter hepatic metabolic enzymes may modify resmetirom’s plasma concentrations.
Co-administration with other lipid-lowering agents may potentiate cholesterol-lowering effects and adverse reactions.
Medication lists should be reviewed regularly to avoid unintended interactions.
Inhibitors or inducers of hepatic transporters (OATP) can alter absorption or excretion.
Herbal supplements with CYP2C8 inhibitory properties may increase resmetirom levels.
Patients should inform healthcare providers of all over-the-counter, prescription, and herbal product use.
Interactions may alter the safety profile requiring closer clinical monitoring.
Use of multiple interacting drugs can compound risks warranting individualized risk assessment.

Preparations Of The Drug

Oral tablet formulation containing active ingredient resmetirom at strengths of 60 mg, 80 mg, and 100 mg.
Tablets possess film coating composed of polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, with red iron oxide for 100 mg and yellow iron oxide for 80 mg and 100 mg tablets.
Inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, and microcrystalline cellulose.
Tablets designed for once-daily oral administration.
Available as prescription-only medication with specific weight-based dosing.
Packaged for storage at room temperature between 68°F to 77°F (20°C to 25°C) to maintain stability.
Produced by Madrigal Pharmaceuticals specializing in liver disease therapeutics.
Manufacturing utilizes advanced pharmaceutical technology for controlled release and bioavailability.
Supplied in blister packs or bottles according to pharmacy dispensing requirements.
Labeling includes patient instructions emphasizing adherence and safety monitoring.
Film coating colors aid in dosage identification and patient compliance.
No generic equivalents currently available, marketed exclusively as Rezdiffra.
Preparation standards comply with FDA accelerated approval regulations.
Includes extensive patient safety information due to potential hepatobiliary effects.
Formulation optimized to enable gastrointestinal tolerability and minimize local irritation.